FREEDOM OF INFORMATION

REF: 2026-73
Subject: Request on the Treatment of Chronic Lymphocytic Leukaemia (CLL)

Dear Sir/Madam,

Thank you for your email dated **27/01/2026** where you requested information about **Request on the Treatment of Chronic Lymphocytic Leukaemia (CLL).**

The information you requested is enclosed.

Please note: that due to the low result numbers, we have added the response of Less than 10, to protect patient identity to both questions 1 and 2

Question	Answer
Q1. How many patients has your Trust treated in the past 12 months (January - December 2025) for Chronic Lymphocytic Leukaemia (CLL)? In case you do not treat CLL, which other Trust do you refer patients needing treatment to?	<10
Q2. How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated by the Trust in the past 6 months on the following treatments:	
• BR (bendamustine + rituximab)	<10
• Brukinsa (zanubrutinib)	
• Calquence (acalabrutinib)	
• Calquence (acalabrutinib) + Gazyva (obinutuzumab)	
• Calquence (acalabrutinib) + Venclyxto (venetoclax)	
• Calquence (acalabrutinib) + Venclyxto (venetoclax) + Gazyva (obinutuzumab)	
• FCR (fludarabine + cyclophosphamide + rituximab)	
• Fludarabine Monotherapy	
• Gazyva (obinutuzumab) + chlorambucil	
• Imbruvica (ibrutinib)	
• Venclyxto (venetoclax)	
• Venclyxto (venetoclax) + Gazyva (obinutuzumab)	

• Venclyxto (venetoclax) + rituximab	
• Zydelig (idelalisib) + rituximab	
• Imbruvica (Ibrutinib) +Venclyxto (venetoclax)	
• Any other systemic anti-cancer therapy	
Q3. How many Chronic Lymphocytic Leukaemia (CLL) patients have received treatment for relapsed/refractory CLL in the past 6 months with the following:	
• Brukinsa (zanubrutinib)	Bolton NHS Foundation Trust unable to answer – please refer to The Christie NHS Foundation Trust
• Calquence (acalabrutinib)	
• Imbruvica (ibrutinib)	
• Venclyxto (venetoclax)	
• Zydelig (idelalisib) + rituximab	
• Any other systemic anti-cancer therapy	
Q4. If your Trust does treat Chronic Lymphocytic Leukaemia patients, do you currently participate in any ongoing clinical trials for the treatment of CLL? If yes, please can you provide details of the ongoing trials.	We do not currently have any research trials open or recruiting for this.

If you have any queries or concerns please do not hesitate to contact the Freedom of Information Department. It would be helpful to quote the above reference number in any future communication.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to The Chief Executive, Bolton NHS Foundation Trust, The Royal Bolton Hospital, Minerva Road, Farnworth, Bolton. BL4 0JR.

If you are not content with the outcome of your complaint you may apply directly to the Information Commissioner. Generally the Information Commissioner cannot make a decision unless you have exhausted the complaints procedure provided by Bolton NHS Foundation Trust. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire. SK9 5AF.

The information supplied to you continues to be protected by the Copyright Design and Patents Act 1998. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication requires the permission of the Trust. You must ensure you gain the Trust permission before reproducing any third party information.

Yours sincerely,

Information Governance Department

Bolton NHS Foundation Trust
01204 390861
FOI@boltonft.nhs.uk
Informatics Building | Opposite N Block | Royal Bolton Hospital

Improving care,
transforming lives...for a better Bolton

Improving care,
transforming lives...for a better Bolton